Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Pouch surgery has long-term costs for young patients

Restorative proctocolectomy with ileal pouch-anal anastomosis is associated with high complication rates and poor body image in patients who undergo the procedure at a young age, research shows, with women at additional risk for sexual dysfunction.

15 Aug 2012

New personal care product for circumcised men

Centric Research Institute today launched CIRCUMserum, the first personal care product formulated specifically for use by circumcised men. CIRCUMserum is a daily moisturizing cream made from a patent-pending blend of essential botanical oils designed to condition areas of the penis dulled by the constant exposure resulting from circumcision.

13 Aug 2012

Doctors sometimes fail to warn patients of particular risks before treatment

Australian doctors sometimes fail to warn patients of risks that could affect the patient's quality of life before providing treatment or surgery, a new study led by University of Melbourne researchers has shown.

9 Aug 2012

Depressive symptoms, suicidal thoughts more prevalent among former finasteride users

New research, to be published in the Journal of Clinical Psychiatry, finds that men who developed persistent sexual side effects while on finasteride (Propecia), a drug commonly used for male pattern hair loss, have a high prevalence of depressive symptoms and suicidal thoughts.

8 Aug 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

Obesity also affects sexual and urinary health in men

As a man's waistline grows, so can his experience with sexual dysfunction and frequent urination, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The study, published in the August issue of the British Journal of Urology International (BJUI), is the first to comprehensively show that obesity in men affects not just their hearts and metabolism, but also their sexual and urinary health.

31 Jul 2012

Diabetic women more likely to report low overall sexual satisfaction

Women with diabetes are just as likely to be interested in, and engage in, sexual activity as non-diabetic women, but they are much more likely to report low overall sexual satisfaction, according to a UCSF study.

26 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Sexual health of female cyclists can be affected by handlebar level

A new study published in The Journal of Sexual Medicine reveals that handlebar position is associated with changes in genital sensation in female cyclists.

9 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012

GlaxoSmithKline agrees to plead guilty, pay $3B settlement

Drugmaker GlaxoSmithKline has agreed to plead guilty to fraud charges and pay $3 billion in total -- with some money going to nearly every state -- for promoting its bestselling antidepressants such as Paxil and Wellbutrin for unapproved uses, failing to report safety data about a top diabetes drug and improperly marketing other drugs.

4 Jul 2012

Palatin announces private placement of common stock and warrants

Palatin Technologies, Inc. today announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shares of its common stock, and Series B warrants to purchase 35,488,380 shares of its common stock.

2 Jul 2012

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.

2 Jul 2012

Nouveau Life explores line of specialty supplements for seniors

Nouveau Life Pharmaceuticals, Inc., a provider of quality all-natural dietary supplements, announced today that the Company is exploring a line of specialty supplements for seniors.

15 Jun 2012

Ventral rectoplexy helps recover sexual function

Laparoscopic ventral rectoplexy may reduce sexual dysfunction in women with complex posterior floor prolapse, say researchers who found many patients appreciated having postoperative investigation of their symptoms.

13 Jun 2012

Consequences of female genital mutilation could be reduced by reconstructive surgery

Reconstructive surgery after female genital mutilation (FGM) appears to reduce pain and restore sexual pleasure in women, according to the first large prospective trial to assess long-term outcomes of a new surgical technique published Online First in The Lancet. Over the past 10 years, between 130 and 140 million women worldwide have been subject to FGM.

12 Jun 2012

BioSante to initiate two new LibiGel Phase III efficacy trials in FSD, HSDD

BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).

11 Jun 2012

Ampio’s CRO completes Optina clinical trial for DME

Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada.

11 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012